Following FDA 510(k) clearance, Excellagen, a product of San Diego-based Cardium Therapeutics, launched their new website designed and developed by Studio 2055. Nanette Newbry, Principal of Studio 2055, collaborated with Cardium CEO Chris Reinhard, along with Excellagen’s lead scientist and public relations specialist in site development.
Planning for the website began years prior to FDA approval when Newbry guided Excellagen through concept development. The goal was to create an online platform to support the company’s collagen-based gel. The product is a topical dressing for foot lesions commonly found on diabetes patients.
The website design process for Excellagen required an experienced team of marketers, designers and programmers who understood the complex facets of branding and web development for the biopharmaceutical sector. Newbry’s thirty years of working in biotech with IVAC (Cardinal Health), Cardium and Eli Lilly provided expert corporate identity and brand positioning knowledge for this new product.
Working from a single logo design, the website framework, design and user-interface was positioned to inform potential investors, enhance public relations and provide product background and patient/doctor information.
The website’s intent was for individuals researching the product to see results from using Excellagen. Photos were centered on the positive outcomes of Excellagen’s wound care. Product illustrations and photo examples were used to accentuate the benefits of the product.
“The Excellagen website project was thoughtful and precise in nature due to the preliminary steps towards FDA clearance,” said Newbry. “Chris and his team were invaluable as we researched complicated material to reveal an intuitive user interface and approachable, intelligent design. The final website successfully exemplifies Excellagen’s position as a leader in wound care.”
